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Disease patterns and incidence of immune-
mediated disease in insured Swedish Nova
Scotia Duck Tolling Retrievers
H. D. Bremer, Å. Vilson, B. N. Bonnett, H. Hansson-Hamlin
In this study, morbidity in insured Nova Scotia Duck Tolling Retriever (NSDTR) dogs from
Sweden was investigated and compared with all other breeds and other retriever breeds.
In addition to describing common morbidities in NSDTRs, the hypotheses that NSDTRs are
predisposed to lymphoma, immune-mediated rheumatic disease (IMRD) and steroid-
responsive meningitis-arteritis (SRMA) were tested. Included in the study were 445,336
dogs; of which, 2890 were NSDTRs that had been covered by veterinary insurance from the
Agria Insurance Company (Stockholm, Sweden) at some point during the years 1995–2006.
Incidences of various health problems were calculated using the number of veterinary visits
as the numerator and the exact time at risk as the denominator. Overall, morbidity was
higher in NSDTRs compared with all other breeds, but similar compared with other retriever
breeds. The most common causes of veterinary visits in NSDTRs were injuries,
gastrointestinal disease and locomotor disorders, with NSDTRs at increased risk of these
compared with all other breeds. The incidences for IMRD, SRMA and lymphoma were
signiﬁcantly higher in NSDTRs than in all other dog breeds and all other retriever breeds. The
study describes morbidity in NSDTRs, and identiﬁes several disorders to which the breed is
predisposed.
Introduction
Nova Scotia Duck Tolling Retriever (NSDTR) dogs can be
affected by several immune-mediated disorders, in particular
immune-mediated rheumatic disease (IMRD) and steroid-
responsive meningitis-arteritis (SRMA) (Redman 2002,
Hansson-Hamlin and Lilliehöök 2009, 2013). Dogs affected by
IMRD are normally middle-aged, and the most prevalent clinical
ﬁnding is chronic pain and stiffness from multiple joints caused
by non-erosive polyarthritis. Sometimes, organ systems other
than the joints can be affected, most commonly the skin. Most
cases are shown to have antinuclear antibodies on indirect
immunoﬂuorescence (Hansson-Hamlin and Lilliehöök 2009).
The clinical signs of IMRD in NSDTRs resemble those seen in
the chronic autoimmune disease, systemic lupus erythematosus
(SLE) or SLE-related disorders; diseases well described in both
human beings and dogs (Lewis and others 1965, Tan 1989,
Fournel and others 1992, Rahman and Isenberg 2008). In human
beings, a diagnosis of SLE is made based on deﬁned criteria
(Tan and others 1982, Hochberg 1997). Similar criteria for the
diagnosis of canine SLE have been proposed (Halliwell 1978,
Grindem and Johnson 1983, Bennett 1987), but they are not well
established, and there is an overlap of clinical and diagnostic ﬁnd-
ings between SLE and SLE-related disorders like IMRD. Overall,
the clinical features of SLE are similar in dogs and human beings.
Similarly, canine lymphoma resembles human lymphoma in
many ways (Richards and Suter 2015). Human patients with
SLE are known to have an increased risk of lymphoma
(Pettersson and others 1992, Mellemkjaer and others 1997),
whether this is the case in dogs, is not known, but the similar-
ities for the disorders between dogs and human beings evoke the
question of whether a similar association can be found in dogs.
SRMA is a disease primarily affecting young dogs. The
typical, acute form is characterised by pain, cervical rigidity,
pyrexia and polymorphonuclear pleocytosis of the cerebrospinal
ﬂuid (Tipold and Jaggy 1994, Tipold and Schatzberg 2010,
Hansson-Hamlin and Lilliehöök 2013). A high prevalence of
SRMA in Norwegian NSDTRs has been reported, suggesting a
breed predisposition (Anﬁnsen and others 2008).
Genome-wide association studies in NSDTRs have shown
that IMRD and SRMA are diseases with complex inheritance
patterns. Loci associated with IMRD and/or SRMA contain
strong candidate genes that are involved in immune regulation
(Wilbe and others 2010). In addition, a particular major histo-
compatibility complex class II haplotype is a genetic risk factor
for IMRD (Wilbe and others 2009).
Previous published studies on immune-mediated diseases in
NSDTRs are mainly case reports or case-control studies
(Hansson-Hamlin and Lilliehöök 2009, 2013; Wilbe and others
2009; Wilbe and others 2010). Such studies can be important in
highlighting a problem within a breed; however, they do not
give any information about the frequency of disease, and do not
prove a breed predisposition. The disease frequency of SRMA in
the Norwegian population of NSDTRs has previously been
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estimated (Anﬁnsen and others 2008), but the relative risk (RR)
compared with dogs of other breeds was not investigated.
Morbidity associated with IMRD has not previously been inves-
tigated. To fully understand the impact of a possible predispos-
ition to a disease in a breed, the disease frequency should be
compared with other breeds and also with other disorders
within the breed.
Population-based epidemiological studies of morbidity in dog
breeds can provide valuable information about genetic predispos-
ition for disease and support disease-prevention strategies.
Insurance data have proven to be a valuable tool for epidemio-
logical studies since it contains information about the back-
ground population as well as the disease events (Egenvall and
others 2009). In Sweden, most dogs are covered by an insurance
plan, and over one-third of the dog population is insured by
Agria Insurance Company, Stockholm, Sweden (Egenvall and
others 1998, Agria 2013).
This study assessed morbidity in NSDTRs using Agria insur-
ance data from the years 1995 to 2006. The ﬁrst aim was to
describe the disease pattern in NSDTRs. The second aim was to
test the hypothesis that NSDTRs are predisposed to IMRD,
SRMA and lymphoma compared with other breeds.
Material and methods
Study population
A retrospective cohort was assembled from insurance data from
Agria Insurance Company. The study population included all
dogs insured before one year of age during the years 1995–2006.
Data were included on 445,336 dogs (219,201 females, 226,135
males, neutering status not available), of which 2890 (1408
females, 1482 males) were NSDTRs. Two comparison groups
were created; the ﬁrst consisting of all dogs except NSDTRs
(442,446 dogs) and the other of all retrievers except NSDTRs
(52,073 dogs).
Information on dog identity, breed, sex, date of birth, dates
when dogs entered and left insurance database, diagnostic codes
for veterinary visits and dates of veterinary visits were collected.
The diagnostic code, best describing the cause of the veterinary
visit, was selected from a standard national diagnostic registry
(Swedish Animal Hospital Organisation 1993) by the attending
veterinarian. If the owner was reimbursed for the cost of the vet-
erinary visit, the cause of visit (the diagnostic code) was regis-
tered in the insurance database. The diagnostic registry and the
insurance process in Agria have previously been described in
detail (Egenvall and others 2000a, b).
Diagnostic classiﬁcation
To describe morbidity in NSDTRs at both general and detailed
levels, diagnostic codes were grouped into 24 level-1 categories
based on organ systems and disease processes. Every category
was further divided into level-2 categories that were further
divided into level-3 categories containing 1–390 diagnostic codes.
The subdivision is exempliﬁed in Table 1.
There is no single diagnostic code for either IMRD or SRMA
in the national diagnostic registry. Therefore, diagnostic codes
that could represent IMRD and SRMA, respectively, were com-
bined to create these classiﬁcations. Two diagnostic groups were
created for each disorder; the ﬁrst, designated ‘IMRD’ and
‘SRMA’, included codes most likely to be used by veterinarians
for these disorders. The second group, designated ‘IMRD/SRMA
possibly ’ included, in addition to those in ‘IMRD/SRMA’
groups, additional codes that may have also been used for dogs
suspected to have these disorders. These non-speciﬁc codes could
have been used for other disorders as well. A table containing all
of the diagnostic codes is included in the online supplementary
material Table S1.
For the purpose of studying lymphoma, two diagnostic
codes ‘lymphosarcoma/malignant lymphoma’ and ‘malignant
lymphoma’ were grouped together since veterinary clinicians
may use them interchangeably.
There was no information on whether or how diagnosis was
conﬁrmed.
Statistical analysis
Incidences were calculated using the number of veterinary visits
as the numerator and the exact time at risk as the denominator.
Prophylactic visits were not counted for. Time at risk for the
dogs was calculated as time from the start of the insurance
policy (or January 1, 1995, if it started earlier) until a disease
event occurred for the particular diagnosis or disease category
studied, or until withdrawal from insurance cover (or at the end
of the study period, ie, December 31, 2006). The incidence was
multiplied by 10,000 and presented as number of cases per
10,000 dog years at risk (DYAR). If a dog had more than one
claim for the investigated diagnosis or disease category, only the
ﬁrst claim was counted.
Since it is rare to diagnose primary cases of SRMA in dogs
older than two years of age (Lowrie and others 2009, Tipold and
Schatzberg 2010, Hansson-Hamlin and Lilliehöök 2013), a condi-
tional analysis for SRMAwas also performed, including only vet-
erinary visits and time at risk for dogs up to two years of age.
Incidences were calculated for NSDTRs as well as for the
two comparison groups, for each sex separately as well as for the
two sexes combined. Calculations were performed using the
software SAS V.9.3 (SAS Institute, Cary, North Carolina, USA).
Exact CIs for incidences were constructed using the epi.conf
function in the R package epiR V.0.9–59 in RV.3.0.2 (R core team
2013). RR values for NSDTRs were calculated by dividing inci-
dence for NSDTRs by incidence for the respective comparison
group. CIs and P values for RR were constructed using the R
package exactci V.1.2–1 (Fay 2010) in R V.3.0.2. The level of sig-
niﬁcance was set to 0.05. For a description of the disease pattern,
correction for multiple comparisons with Bonferroni correction
was performed in addition to calculating raw P values.
Results
Of the 2890 NSDTRs in the study, 51 per cent had at least one
veterinary visit between 1995 and 2006. For all other breeds com-
bined, the proportion of dogs with at least one veterinary visit
was 43 per cent. For retrievers, the proportion was 52 per cent.
The average number of veterinary visits per dog was 2.2 for
NSDTRs, 1.7 for all other breeds combined and 2.1 for other
TABLE 1: Hierarchical distribution of original diagnostic codes
and level-3 categories within autoimmune causes* (level 2)
of veterinary visits
Level 2 Level 3 Diagnostic code
Autoimmune Autoimmune
blood
Autoimmune haemolytic anaemia
Autoimmune thrombocytopenia
Autoimmune skin Autoimmune skin diseases
Cold haemagglutinin disease
Dermatomyositis
Pemphigus
Pemphigus vulgaris
Pemphigus vegetans
Pemphigus foliaceus
Pemphigus erythematosus
Bullous pemphigoid
Lupus Discoid lupus erythematosus
Systemic lupus erythematosus
Myasthenia gravis Myasthenia gravis
Rheumatological Immune-related condition, specified by
each joint†
Immune-related condition, several joints
Rheumatoid arthritis, specified by each
joint†
Rheumatoid arthritis, several joints
Signs of rheumatological disease
*From level-1 category ‘Immunological’ disorders
†Several diagnostic codes available, specified by the joint affected
Veterinary Record | July 18, 2015
Paper
group.bmj.com on March 4, 2016 - Published by http://veterinaryrecord.bmj.com/Downloaded from 
retrievers. Excluding the 49 per cent of NSDTRs that did not
experience a veterinary visit, the number of visits per dog was
4.3. The incidence for veterinary visits in NSDTRs was 1300
cases per 10,000 DYAR, with a RR of 1.1 (95 per cent CI 1.0 to
1.1, P=0.0075) compared with all other breeds combined.
Compared with other retrievers combined, the RR was 0.96
(95 per cent CI 0.91 to 1.0, P=0.091).
In Table 2, incidences and RR in NSDTRs for level-1 cat-
egories are presented. The most common level-1 causes of vet-
erinary visits in NSDTRs were injuries, gastrointestinal
disease and locomotor disorders, with an increased risk
among NSDTRs evident compared with all other breeds (also
after Bonferroni correction). Compared with all other breeds,
NSDTRs were at decreased risk of ear and heart disorders,
heart disorders being less common in NSDTRs (also after
Bonferroni correction).
The incidence for the level-1 category immunological disor-
ders in NSDTRs was approximately the same as in all other
breeds and retriever breeds (Tables 2 and 3). Immunological disor-
ders consisted of three level-2 categories, ‘allergic’, ‘autoimmune’
and ‘immune, various’, which are presented in Table 3. ‘Allergic’
was the most common level-2 category of immunological disor-
ders in NSDTRs, with a similar incidence in NSDTRs compared
with other breeds and retrievers. Autoimmune disorders and
remaining immunological disorders, not classiﬁed as auto-
immune or allergies (named ‘immune, various’), were signiﬁ-
cantly more common in NSDTRs than in other breeds and
retrievers (Table 3).
The incidence for the level-1 category neurological disorders
was higher in NSDTRs than in other breeds and retrievers
(Tables 2 and 4). Neurological infection/inﬂammation was the
most common level-2 category of neurological disorders in
NSDTRs, and was nine times more common in NSDTRs than
in other breeds (Table 4). Epilepsy was less common in NSDTRs,
and the risk was signiﬁcantly decreased compared with retrievers
(Table 4).
Morbidity was assessed on a more detailed level where
level-2 categories were divided into level-3 categories. Table 5
includes incidences and RRs in NSDTRs for the 15 most
common level-3 categories. The most common was ‘vomiting/
diarrhoea/gastroenteritis’, which had an incidence similar to all
other breeds and retriever breeds. Among the top 15 most
common level-3 categories, NSDTRs had the highest RR for
‘pain/stiffness’ (RR 2.7 compared with other breeds, RR 2.4
compared with retrievers).
Presented in Fig 1 are the 15 level-3 categories with the
highest RRs in NSDTRs compared with all other breeds. Only
signiﬁcant (P<0.05) ﬁndings are presented, and categories signiﬁ-
cantly more common in NSDTRs than in other breeds and
retriever breeds after Bonferroni corrections are marked in the
ﬁgure. Compared with all other breeds, NSDTRs had the highest
risk of unspeciﬁed immune disorders and CNS infections/inﬂam-
mations (Fig 1). Unspeciﬁed immune disorders included various
immune disorders, not autoimmune or allergic, and not related
to the skin, muscle, eyes or claws. The most common diagnostic
codes of unspeciﬁed immune disorders in NSDTRs were
‘immune-related conditions, oral cavity/throat’ followed by
‘immunological changes, whole animal’ and ‘immune-related
conditions, spinal cord membranes’.
Immune-mediated rheumatic disease
Of the 2890 NSDTRs in the study, 0.35 per cent had an ‘IMRD’
diagnosis, and 3.3 per cent had an ‘IMRD possibly’ diagnosis.
The most common diagnostic codes in the ‘IMRD possibly’
group were ‘signs of generalised pain’ and ‘signs of general stiff-
ness’, both codes being signiﬁcantly more common
(P=6.5×10−7; 1.1×10−5) in NSDTRs than in other breeds, when
analysed individually.
The incidence in NSDTRs and RR values for the diagnostic
groups representing IMRD (see online supplementary Table S1)
are presented in Table 6. The incidence for ‘IMRD’ was 6.8 cases
per 10,000 DYAR with an 18 times increased risk in NSDTRs
compared with all other breeds (95 per cent CI 8.5 to 36) and a
30 times increased risk compared with other retriever breeds
(95 per cent CI 9.9 to 100). For ‘IMRD possibly’, which included
some non-speciﬁc diagnostic codes, incidence was higher and RR
TABLE 2: Incidences and relative risk for level-1 causes of veterinary visits in NSDTRs
Incidence, NSDTR
Cases/10,000 DYAR (95% CI)
Relative risk/all other
breeds (95% CI) P value
Relative risk/retrievers
(95% CI) P value
Injury*† 310 (280 to 340) 1.4 (1.2 to 1.5) 4.4×10−9 1.3 (1.2 to 1.4) 6.7×10−7
Gastrointestinal* 310 (270 to 340) 1.2 (1.1 to 1.3) 0.0012 1.1 (1.0 to 1.3) 0.017
Locomotor* 270 (240 to 300) 1.2 (1.1 to 1.4) 2.5×10−4 0.94 (0.84 to 1.0) 0.23
Neoplasia 250 (230 to 280) 1.1 (1.1 to 1.3) 0.021 0.87 (0.78 to 0.97) 0.013
Skin 250 (220 to 280) 1.2 (1.1 to 1.3) 0.0028 1.1 (0.97 to 1.2) 0.16
Signs/whole body*† 190 (170 to 220) 1.4 (1.2 to 1.6) 5.8×10−7 1.3 (1.1 to 1.4) 4.4×10−4
Reproductive/female‡ 140 (120 to 160) 0.88 (0.76 to 1.0) 0.061 0.72 (0.63 to 0.83) 2.8×10−6
Eyes 91 (77 to 110) 1.2 (0.97 to 1.4) 0.11 1.2 (0.99 to 1.4) 0.063
Respiratory/upper 76 (63 to 92) 0.90 (0.74 to 1.1) 0.27 1.0 (0.84 to 1.3) 0.82
Infection 76 (63 to 91) 1.3 (1.1 to 1.6) 0.0048 0.99 (0.81 to 1.2) 0.98
Ear‡ 71 (59 to 87) 0.77 (0.63 to 0.94) 0.0074 0.47 (0.39 to 0.58) <2.2×10−16
Neurological*† 68 (56 to 83) 1.7 (1.4 to 2.1) 7.6×10−7 1.6 (1.3 to 2.0) 3.8×10−5
Urinary/lower 52 (41 to 65) 0.82 (0.65 to 1.0) 0.093 0.95 (0.75 to 1.2) 0.75
Reproductive/male 46 (36 to 58) 1.3 (1.0 to 1.7) 0.029 2.0 (1.5 to 2.6) 9.2×10−7
Immunological 44 (35 to 56) 1.3 (0.99 to 1.6) 0.064 1.2 (0.91 to 1.5) 0.20
Blood/vascular*† 34 (26 to 45) 2.1 (1.5 to 2.7) 6.5×10−6 1.7 (1.3 to 2.3) 7.3×10−4
Endocrine 30 (22 to 40) 0.96 (0.69 to 1.3) 0.83 0.86 (0.62 to 1.2) 0.37
Respiratory/lower 20 (14 to 29) 0.76 (0.51 to 1.1) 0.15 1.1 (0.71 to 1.5) 0.77
Heart§ 20 (14 to 29) 0.55 (0.37 to 0.78) 3.7×10−4 0.86 (0.59 to 1.2) 0.50
Urinary/upper 14 (9.4 to 22) 0.77 (0.48 to 1.2) 0.26 0.75 (0.46 to 1.2) 0.22
Operation/complication 9.5 (5.7 to 16) 1.3 (0.70 to 2.2) 0.42 1.4 (0.73 to 2.3) 0.33
Claw 7.5 (4.2 to 13) 1.0 (0.52 to 1.9) 0.96 0.90 (0.44 to 1.6) 0.88
Behaviour 2.7 (1.1 to 6.9) 1.9 (0.52 to 5.0) 0.32 2.5 (0.63 to 7.1) 0.19
Respiratory/thoracic 2.0 (0.74 to 5.9) 0.79 (0.16 to 2.3) 0.95 0.62 (0.13 to 1.9) 0.59
Ranked by incidence
Relative risk=incidence for NSDTR/incidence for comparison group
*Increased risk in NSDTRs compared with all breeds after correction for multiple comparisons (Bonferroni n=24)
†Increased risk in NSDTRs compared with retrievers after correction for multiple comparisons (Bonferroni n=24)
‡Decreased risk in NSDTRs compared with retrievers after correction for multiple comparisons (Bonferroni n=24)
§Decreased risk in NSDTRs compared with all breeds after correction for multiple comparisons (Bonferroni n=24)
DYAR, dog years at risk; NSDTR, Nova Scotia Duck Tolling Retriever
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lower than for ‘IMRD’, but still signiﬁcantly higher than in all
other breeds (Table 6).
The incidence for ‘IMRD’ was higher in female NSDTRs
than in male NSDTRs (RR 8.9, 95 per cent CI 1.3 to 390,
P=0.023), but no sex difference were observed in the ‘IMRD pos-
sibly ’ category. In all other breeds combined, and in all other
retriever breeds combined, there was no sex difference in inci-
dence for ‘IMRD’, but the incidence for ‘IMRD possibly’ was
higher in males (RR all other breeds 1.4, 95 per cent CI 1.3 to
1.5, P=2.2×10−16; RR in other retrievers 1.4, 95 per cent CI 1.2
to 1.7, P=7.9×10−16).
Steroid-responsive meningitis-arteritis
Of the 2890 NSDTRs, 1.0 per cent had an ‘SRMA’ diagnosis, and
1.2 per cent had an ‘SRMA possibly ’ diagnosis. The diagnostic
code ‘meningitis’ was the most common code in the two diag-
nostic groups.
The incidences in NSDTRs and RR values for the diagnostic
groups representing SRMA (see online supplementary Table S1)
are presented in Table 7. The incidence for ‘SRMA’ in NSDTRs
was 20 per 10,000 DYAR, 12 times higher than in all other
breeds (95 per cent CI 7.6 to 17) and 21 times higher than in
other retriever breeds (95 per cent CI 12 to 37). When excluding
cases and time at risk in dogs above two years of age, the inci-
dence for ‘SRMA’ was 53 cases per 10,000 DYAR.
There was no difference in incidences between females and
males for ‘SRMA’ in NSDTRs, in all other breeds combined or in
all other retriever breeds. The incidence for ‘SRMA possibly’ was
1.2 times higher in males than in females (95 per cent CI 1.0 to
1.5, P=0.041) of all other breeds combined. There was no sex
difference for ‘SRMA possibly ’ in NSDTRs or in other retrievers.
Lymphoma
The incidence for lymphoma (‘lymphosarcoma/malignant
lymphoma’ and ‘malignant lymphoma’ combined) in NSDTRs
was 15 cases per 10,000 DYAR (95 per cent CI 9.9 to 23).
NSDTRs had a signiﬁcant increased risk compared with all other
breeds (RR 2.8, 95 per cent CI 1.8 to 4.3, P=4.9×10−5) as well as
to other retriever breeds (RR 2.0, 95 per cent CI 1.2 to 3.1,
P=0.0067). None of the NSDTR dogs with a lymphoma diagno-
sis did have an IMRD or SRMA diagnosis.
Discussion
Immune-mediated diseases have previously been reported to be a
problem in NSDTRs, with two disorders being particularly
recognised: IMRD and SRMA (Redman 2002, Anﬁnsen and
others 2008, Hansson-Hamlin and Lilliehöök 2009, 2013).
Although previous studies have suggested that NSDTRs are pre-
disposed to IMRD and SRMA, the RR compared with other dog
breeds has not been evaluated.
The Swedish dog population has been estimated to be
700,000 to 800,000 individuals (Egenvall and others 1999, Agria
2013, Swedish Board of Agriculture 2014); of which, approxi-
mately 0.5 per cent were NSDTRs at the end of 2013 (Swedish
Board of Agriculture 2014). The number of dogs included in the
present study was over 400,000. Hence, it represented a large
proportion of the Swedish dog population over several years, and
the proportion of NSDTRs was approximately the same as pre-
viously published.
The main advantage of using insurance data is that it is pos-
sible to estimate incidence of disease. The Agria insurance data-
base is validated for epidemiological studies, and it has been used
in multiple studies to assess morbidity in dogs (Egenvall and
others 1998, 1999, 2009; Nodtvedt and others 2006; Fall and
others 2007; Vilson and others 2013). Even so, the database was
not developed to study morbidity primarily for research pur-
poses, and limitations have to be recognised. First of all, the diag-
nostic codes used to assess morbidity are assigned by the
attending veterinarian, and no information about diagnostic
accuracy is available. However, the agreement between the data-
base and veterinary records has been evaluated and considered
fair and similar across breeds (Egenvall and others 1998). It is
unknown to what extent morbidity ﬁndings based on insurance
data can be applied to an uninsured population.
The general description of disease patterns presented here
provides unique information about morbidity in NSDTRs.
High-risk disorders were identiﬁed, and also the most common
disorders in the breed. The purpose of comparing NSDTRs with
other retrievers was to create a comparison group with dogs that
live under similar environmental conditions, and are used for
similar activities. NSDTRs had a slightly increased risk of disease
compared with all other dog breeds combined, but a similar risk
compared with other retrievers. Increased risk for several groups
TABLE 3: Incidences and relative risk for immunological causes of veterinary visits in NSDTRs
Incidence, NSDTR
Cases/10,000 DYAR (95% CI)
Relative risk/all other
breeds (95% CI) P value
Relative risk/retrievers
(95% CI) P value
Level 1
Immunological 44 (35 to 56) 1.3 (0.99 to 1.6) 0.064 1.2 (0.91 to 1.5) 0.20
Level 2
Allergic 22 (16 to 31) 0.78 (0.53 to 1.1) 0.18 0.72 (0.50 to 1.0) 0.068
Autoimmune 13 (8.3 to 20) 2.7 (1.3 to 5.1) 2.5×10−4 2.7 (1.6 to 4.3) 5.9×10−4
Immune, various 8.8 (5.1 to 15) 3.9 (2.1 to 6.7) 1.1×10−4 3.8 (1.9 to 7.1) 2.4×10−4
Level-2 categories in the level-1 category ‘immunological’ are presented
Relative risk=incidence for NSDTR/incidence for comparison group
DYAR, dog years at risk; NSDTR, Nova Scotia Duck Tolling Retriever
TABLE 4: Incidences and relative risk for neurological causes of veterinary visits in NSDTRs
Incidence, NSDTR
Cases/10,000 DYAR (95% CI)
Relative risk/all other
breeds (95% CI) P value Relative risk/retrievers (95% CI) P value
Level 1
Neurological 68 (56 to 83) 1.7 (1.4 to 2.1) 7.6×10−7 1.6 (1.3 to 2.0) 3.8×10−5
Level 2
Neurological inf/infl 28 (21 to 39) 9.0 (6.4 to 12) <2.2×10−16 12 (8.0 to 18) <2.2×10−16
Neurological, various 25 (18 to 35) 1.7 (1.2 to 2.3) 0.0042 1.6 (1.1 to 2.2) 0.017
Epilepsy 16 (10 to 23) 0.70 (0.44 to 1.1) 0.092 0.61 (0.39 to 0.93) 0.018
Level-2 categories in the level-1 category ‘neurological’ are presented
Relative risk=incidence for NSDTR/incidence for comparison group
DYAR, dog years at risk; inf/infl, infection/inflammation; NSDTR, Nova Scotia Duck Tolling Retriever
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of disorders were found; however, the RR values have to be con-
sidered when interpreting the results; in some instances, the inci-
dence was only slightly higher than in other breeds, and the
lower conﬁdence limit was close to 1.0. This study was an obser-
vational study, and it was not the aim, and it is not possible, to
draw deﬁnite conclusions about the cause of increased risk.
Increased risk in a breed can reﬂect a genetic predisposition, but
can, sometimes, be explained by lifestyle factors or owners’ atti-
tudes to seeking veterinary care, factors that can vary between
breeds. In the case of reproductive disorders, the incidence is
affected by neutering, and neutering frequency might vary
between breeds.
The incidences for IMRD, SRMA and lymphoma, which were
signiﬁcantly higher in NSDTRs than in other breeds and other
retrievers, show that these disorders are more common in
NSDTRs. The high RRs observed and the fact that heritable risk
factors contribute to these disorders (Wilbe and others 2009, 2010;
Richards and Suter 2015) indicate a breed predisposition. However,
point estimates for RRs should be extrapolated cautiously, given
that the CIs may be rather wide. The authors could not ﬁnd an
association between lymphoma and IMRD at an individual level
as hypothesised, but they think that a possibly defective immune
regulation in the NSDTR breed makes them predisposed to both
immune-mediated disorders and lymphoma.
IMRD was more common in female NSDTRs than in males,
but was equally common in both sexes in all other breeds.
Previous studies on this disorder in NSDTRs have not indicated
a sex predisposition (Hansson-Hamlin and Lilliehöök 2009). In
human beings, autoimmune disease in general, and SLE in par-
ticular, is more common in females than in males (Whitacre and
others 1999).
The general lack of population-based epidemiological studies
for immune-related disorders like IMRD and SRMA makes com-
parisons of incidences difﬁcult. The cumulative prevalence of
SRMA in Norwegian NSDTRs has been estimated to be 2.5 per
cent, 95 per cent CI 0.9 to 4.1 per cent (Anﬁnsen and others
2008). It is difﬁcult to exactly compare disease frequency in this
study with the cumulative prevalence of 2.5 per cent, but 1 per
cent of NSDTRs in this study had an SRMA diagnosis, which is
within the conﬁdence limits of the Norwegian study.
The incidences in this study may be lower than the true inci-
dence. One reason is that only veterinary visits for which the
owner was reimbursed for the cost of the visit were included. If
the cost of the veterinary visit was low or if the owners had not
sought veterinary care, the visit was not counted. In this study,
only the ﬁrst claim for a particular diagnosis or group of disor-
ders was counted, which might underestimate the total disease
burden of the population, although presumably not the inci-
dence. The comparison between breeds should not be affected,
since the effects should be similar across breeds. There could be a
risk that the knowledge about SRMA and IMRD in NSDTRs
could lead to some NSDTRs being misdiagnosed on the basis of
diagnostic suspicion bias, but since the disorders were ﬁrst
reported in NSDTRs in 2002 (Redman 2002) and 2009
(Hansson-Hamlin and Lilliehöök 2009), and the study period is
1995–2006, the authors do not think this factor has affected the
results. Further support for the present study ﬁnding is that the
authors can show predisposition at different levels for immune-
mediated and neurological disease, not just particular diagnoses.
The choice of diagnostic codes to be included to represent
IMRD and SRMA was challenging. This is particularly true for
IMRD where strict criteria for disease are lacking, and the clin-
ical signs of SLE, IMRD and other SLE-related diseases may be
similar. It should be noted that some diagnostic codes included
were descriptions of clinical signs, rather than aetiology, which
Immune unspecified*#
CNS infl/infl*#
Tear duct various*#
Rheumatological*#
Lupus
Blood/lymphatic vessels inf/infl
Hernia*#
Eye tumour*
Salivary various
Pain/stiffness*#
Mouth/throat various
Liver inf/infl#
Fever/temperature change*#
Lymphosarcoma
Poisoning*
2.9×10–8
2.2×10–16
1.4×10–8
9.2×10–5
0.0014
9.1×10–4
2.7×10–7
3.5×10–6
0.0064
1.4×10–10
0.0085
1.8×10–4
1.6×10–6
1.8×10–4
8.5×10–5
1 15105 20
Relative risk with 95% CI p value
FIG 1: Relative risk for level-3 categories in Nova Scotia Duck Tolling
Retrievers compared with all other breeds. Top 15 level-3 categories
for those with rates different (P<0.05) from other breeds. inf/inﬂ,
infection/inﬂammation. *Increased risk compared with all other
breeds after correction for multiple comparisons (Bonferroni n=339).
#Increased risk compared with retrievers after correction for
multiple comparisons (Bonferroni n=339)
TABLE 5: Most common level-3 causes of veterinary visits in NSDTR
Incidence, NSDTR
Cases/10,000 DYAR (95% CI)
Relative risk/all other
breeds (95% CI) P value
Relative risk/retrievers
(95% CI) P value
Vomiting/diarrhoea/gastroenteritis 170 (150 to 190) 1.1 (0.92 to 1.2) 0.46 0.97 (0.85 to 1.1) 0.70
Locomotor pain/signs* 120 (100 to 140) 1.5 (1.3 to 1.7) 7.8×10−7 1.0 (0.85 to 1.2) 1
Skin trauma 110 (97 to 130) 1.3 (1.1 to 1.5) 0.0019 1.3 (1.1 to 1.5) 0.0034
Pyometra/endometritis† 110 (95 to 130) 0.89 (0.76 to 1.0) 0.17 0.70 (0.59 to 0.82) 2.5×10−6
Skin tumour 100 (89 to 120) 1.2 (1.0 to 1.4) 0.043 0.80 (0.67 to 0.93) 0.0047
Anal/perianal*‡ 82 (68 to 98) 1.8 (1.5 to 2.1) 1.6×10−8 2.8 (2.3 to 3.4) <2.2×10−16
Dermatitis/pyoderma/folliculitis† 78 (65 to 93) 0.88 (0.73 to 1.1) 0.20 0.64 (0.52 to 0.77) 6.2×10−7
Mammary tumour 66 (53 to 80) 1.0 (0.83 to 1.3) 0.86 1.3 (1.0 to 1.6) 0.026
Otitis† 65 (53 to 80) 0.80 (0.65 to 0.98) 0.028 0.58 (0.47 to 0.72) 3.2×10−8
Respiratory upper inf/infl 61 (50 to 75) 0.90 (0.72 to 1.1) 0.35 1.1 (0.85 to 1.3) 0.58
Teeth* 61 (49 to 75) 1.6 (1.3 to 1.9) 9.8×10−5 1.4 (1.1 to 1.8) 0.0030
Claw trauma 52 (41 to 65) 1.6 (1.3 to 2.0) 1.6×10−4 1.1 (0.84 to 1.4) 0.61
Signs of tiredness 45 (36 to 58) 1.5 (1.2 to 1.9) 0.0023 1.1 (0.81 to 1.4) 0.70
Pain/stiffness*‡ 40 (31 to 52) 2.7 (2.0 to 3.5) 1.4×10−10 2.4 (1.8 to 3.2) 1.3×10−8
Itching 40 (31 to 51) 0.95 (0.72 to 1.3) 0.75 0.89 (0.67 to 1.2) 0.41
Ranked by incidence, top 15 shown
Relative risk=incidence for NSDTR/incidence for comparison group
*Increased risk in NSDTRs compared with all breeds after correction for multiple comparisons (Bonferroni n=339)
†Decreased risk in NSDTRs compared with retrievers after correction for multiple comparisons (Bonferroni n=339)
‡Increased risk in NSDTRs compared with retrievers after correction for multiple comparisons (Bonferroni n=339)
DYAR, dog years at risk; inf/infl, infection/inflammation; NSDTR, Nova Scotia Duck Tolling Retriever
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could have led to misclassiﬁcation of some cases. The diagnostic
codes representing SRMA and IMRD were chosen based on pub-
lished descriptions of the diseases in NSDTRs and the authors’
clinical experience. The choices were also validated by checking
the diagnostic codes in primary clinical records from NSDTRs
with a high suspicion of IMRD or SRMA. These records, which
contained information from the years 2002 to 2013, have been
collected with the owner ’s consent, and used for the purpose of
previous studies (Hansson-Hamlin and Lilliehöök 2009, 2013).
This validation revealed that dogs with SRMA often receive the
diagnostic code ‘meningitis’. In contrast, dogs with IMRD are
assigned a variety of diagnostic codes, the most common being
‘lameness’. In the Agria database, ‘lameness’ was the most
common diagnostic code in all NSDTRs (data not shown), prob-
ably reﬂecting a large range of different disorders. Some dogs
with IMRD might have been assigned this diagnostic code, but
the authors decided it to be too unspeciﬁc to be included in
‘IMRD possibly ’.
NSDTRs had signiﬁcantly higher incidences for IMRD and
SRMA than other breeds for both the more and less speciﬁc diag-
nostic classiﬁcations (Tables 6 and 7). The purpose of creating
two diagnostic groups for each disease was to estimate a valid
range for the incidence. The results from the study can be inter-
preted such that the true incidence for IMRD and SRMA is in
the range between the incidence for ‘IMRD/SRMA’ and the inci-
dence for ‘IMRD/SRMA possibly’. Only one diagnosis within
the ‘IMRD/SRMA possibly ’ group was sufﬁcient to make a diag-
nosis, meaning this group probably includes dogs with other dis-
orders as well. The RR for ‘IMRD/SRMA possibly‘ was lower
than for ‘IMRD/SRMA’, which is expected when including more
unspeciﬁc diagnoses that can equally affect or be more common
in some other breeds.
Unfortunately, it was not possible to differentiate SRMA
from meningitis of other origins due to a lack of a more speciﬁc
diagnostic code in the registry. Conditional analyses, which only
included dogs diagnosed before two years of age, were performed
to increase the speciﬁcity. This approach produced increased inci-
dences, but the RR was basically unaffected. Given that the
diagnostic accuracy should not differ between NSDTRs and
other breeds, the RR values should be valid.
The authors think that the disease patterns and breed predis-
positions described here are still relevant in the Swedish dog
population today. The present study results, which are based on
insurance data from 1995 to 2006, have been compared with
newer insurance data from Agria (data not presented), and the
authors found agreement at various levels. For example, similar
to results in the present study (Table 2), the most common
causes of veterinary visits in NSDTRs in the years 2006–2011
were neoplasia, gastrointestinal and locomotor disorders, fol-
lowed by trauma (B. N. Bonnett, personal communication).
Causes of veterinary visits with the highest RR values were
unspeciﬁed immune disorders and CNS infection/inﬂammation,
also in agreement with the results of the present study (Fig 1).
In conclusion, the results show that NSDTRs are at similar
risk of disease, in general, to other retriever breeds, and are at a
slightly higher risk of disease compared with all other breeds
combined. The authors describe morbidity in NSDTRs, and
show that NSDTRs are predisposed to autoimmune and neuro-
logical disorders in general and particularly to IMRD and SRMA.
The authors further show that NSDTRs have an increased risk
of lymphoma compared with other breeds. The information
gained is of value to breeders, dog owners and veterinarians, and
can be used for preventive measures as well as in disease investi-
gations. Research to functionally characterise the genetic risk
factors for IMRD and SRMA in NSDTRs is in progress.
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